Prescriber Criteria Form

Opioids ER 2024 PA Fax 2493-A v2 010124.docx Extended-Release Opioid Analgesics

Conzip (tramadol hydrochloride extended-release), Hysingla ER (hydrocodone bitartrate extended-release tablets), Methadone 5 mg, 10 mg (methadone hydrochloride tablets), Methadone Intensol 10 mg/ml (methadone oral concentrate), Methadone 5 mg/5 ml 10 mg/5 ml Oral Soln (methadone oral solution), MS Contin (morphine extended-release tablets), Nucynta ER (tapentadol extended-release tablets), Oxycontin (oxycodone hydrochloride extended-release tablets), Xtampza ER (oxycodone extended-release capsules), Morphine Extended-Release Capsules, Hydromorphone Hydrochloride Extended-Release Tablets, Hydrocodone Bitartrate Extended-Release Capsules, Oxymorphone Hydrochloride Extended-Release Tablets

Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**.

Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process.

When conditions are met, we will authorize the coverage of Extended-Release Opioid Analgesics.

Drug Name (select from list of drugs shown):

Patient Name:			
Patient ID:			
Patient DOB:	Patient Phone:		
Prescriber Name:			
Prescriber Address:			
City:	State:	Zip:	
Prescriber Phone:	Prescriber Fax:	·	
Diagnosis:	ICD Code(s):		
_		_	

1	Is the requested drug being prescribed for pain associated with cancer, sickle cell	Yes	No
	disease, a terminal condition, or pain being managed through palliative care?		
	[If yes, then no further questions.]		
2	Is the requested drug being prescribed for pain severe enough to require daily, around-the-clock, long-term treatment in a patient who has been taking an opioid? [If no, then no further questions.]	Yes	No
3	Can the patient safely take the requested dose based on their history of opioid use? [Note: This drug should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] [If no, then no further questions.]	Yes	No
4	Has the patient been evaluated, and will the patient be monitored for the development of opioid use disorder? [If no, then no further questions.]	Yes	No

5	Is this request for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days? [If yes, then no further questions.]	Yes	No		
6	Has the patient taken an immediate-release opioid for at least one week?	Yes	No		
Comme	ents:				
	ing this form, I attest that the information provided is accurate and true as of this date and entation supporting this information is available for review if requested by the health plan.	that the			
Prescriber (or Authorized) Signature: Date:					